Haemonetics to Buy Vivasure for €100M, Bolstering Cardiac Surgery Tools
The acquisition adds a novel, fully absorbable vascular closure device, strengthening Haemonetics' position in the high-growth structural heart market.
Haemonetics (NYSE: HAE) has agreed to acquire Vivasure Medical for an upfront payment of €100 million, a strategic move to enhance its portfolio of devices for complex heart surgeries and interventional procedures.
The deal, which also includes potential future payments of up to €85 million tied to milestones, gives Haemonetics control of Vivasure’s PerQseal Elite system. This fully absorbable, patch-based technology is designed to close large-bore openings in blood vessels, a common requirement in rapidly growing procedures like transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair.
The acquisition strengthens Haemonetics' Vascular Closure business, a key component of its strategy to pivot towards higher-growth, higher-margin markets. The company, which has a market capitalization of approximately $4 billion, will fund the acquisition using its existing cash reserves. Shares of Haemonetics rose on the news, closing up 1.25% at $84.04 in Thursday's trading session.
Vivasure's technology is a significant addition for Haemonetics. The PerQseal system is a sutureless and fully bioabsorbable patch that provides a secure closure of arteries and veins up to 26F in size. Its key advantage, as highlighted in clinical studies, is its ability to achieve rapid hemostasis without the need for a 'pre-close' technique, simplifying the surgical workflow. This efficiency is a critical factor as demand for minimally invasive cardiac procedures escalates.
The device has already secured a CE Mark in Europe for both arterial and venous applications. Vivasure submitted a Premarket Approval application to the U.S. Food and Drug Administration (FDA) in 2025 for the arterial version, positioning Haemonetics for a significant market opportunity upon approval.
“The acquisition of Vivasure Medical is a strategic step that strengthens our presence in the interventional cardiology and structural heart markets,” said a Haemonetics spokesperson. “Vivasure’s innovative technology complements our existing portfolio and will help us provide more comprehensive solutions to our customers.”
The move builds upon Haemonetics' established V-PAD technology and expands its reach into the hospital's Interventional Cardiology and Interventional Radiology departments. The global market for large-bore vascular closure devices is experiencing robust growth, driven by an aging population and the increasing adoption of catheter-based therapies over traditional open surgery.
Investors reacted positively to the strategic rationale, seeing the deal as a clear effort to capture a larger share of the advanced surgical device market. The upfront payment of approximately $117 million represents a calculated investment into a technology with a clear path to commercialization in the lucrative U.S. market, pending FDA approval.
As of its latest reporting, Haemonetics held a strong cash position, enabling the company to pursue such bolt-on acquisitions without taking on new debt. The company is scheduled to report its third-quarter fiscal 2026 results on February 5, when management is expected to provide further details on the integration of Vivasure and its outlook for the expanded Hospital business unit.